Raphi Levy Sells 32,500 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 32,500 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00. Following the transaction, the chief financial officer owned 147,680 shares in the company, valued at $1,599,374.40. The trade was a 18.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Alpha Tau Medical Stock Performance

DRTS opened at $9.35 on Friday. The firm has a market capitalization of $844.55 million, a PE ratio of -13.96 and a beta of 1.19. Alpha Tau Medical Ltd. has a twelve month low of $2.82 and a twelve month high of $11.62. The firm’s 50-day moving average price is $8.59 and its 200 day moving average price is $6.98. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.09.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). As a group, sell-side analysts expect that Alpha Tau Medical Ltd. will post -0.67 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on DRTS shares. LADENBURG THALM/SH SH boosted their price target on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Zacks Research raised shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Alpha Tau Medical in a research note on Tuesday. Barclays raised their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $12.60.

Hedge Funds Weigh In On Alpha Tau Medical

A number of hedge funds have recently made changes to their positions in DRTS. Trifecta Capital Advisors LLC purchased a new position in shares of Alpha Tau Medical during the 4th quarter worth approximately $48,000. Envestnet Asset Management Inc. purchased a new position in shares of Alpha Tau Medical during the 3rd quarter worth approximately $62,000. Bank of America Corp DE boosted its position in shares of Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after purchasing an additional 21,677 shares during the period. Wells Fargo & Company MN boosted its position in shares of Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after purchasing an additional 17,500 shares during the period. Finally, Principal Financial Group Inc. purchased a new position in shares of Alpha Tau Medical during the 1st quarter worth approximately $132,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.